Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 74 entries
View as:

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Phase: N/A Priority: Normal
NCT ID: NCT05135715 Org: User:
Start: 04/19/22 End: 12/30/25 Due: 12/30/26

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT04905212 Org: User:
Start: 11/04/21 End: 11/09/23 Due: 11/09/24

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03507166 Org: User:
Start: 12/28/17 End: 10/29/18 Due: 10/29/19

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06038396 Org: User:
Start: 08/03/23 End: 08/31/26 Due: 08/31/27

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06883630 Org: User:
Start: 03/13/25 End: 07/31/27 Due: 07/31/28

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05302284 Org: User:
Start: 06/14/22 End: 04/30/28 Due: 04/30/29

Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT04270669 Org: User:
Start: 04/15/20 End: 10/29/21 Due: 10/29/22

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Phase: N/A Priority: Normal
NCT ID: NCT05306574 Org: User:
Start: 06/20/22 End: 03/02/27 Due: 03/02/28

A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06549959 Org: User:
Start: 08/05/24 End: 12/31/24 Due: 12/31/25

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06221748 Org: User:
Start: 02/22/24 End: 12/31/27 Due: 12/31/28

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Phase: N/A Priority: Normal
NCT ID: NCT05514158 Org: User:
Start: 09/28/22 End: 09/30/24 Due: 09/30/25

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04073602 Org: User:
Start: 08/19/19 End: 01/31/23 Due: 01/31/24

A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04302103 Org: User:
Start: 07/07/20 End: 02/11/22 Due: 02/11/23

A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04311034 Org: User:
Start: 09/26/18 End: 05/30/22 Due: 05/30/23

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06962865 Org: User:
Start: 06/15/25 End: 12/31/27 Due: 12/31/28

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT05247203 Org: User:
Start: 05/11/22 End: 11/13/23 Due: 11/13/24

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Phase: N/A Priority: Normal
NCT ID: NCT02885610 Org: User:
Start: 12/31/15 End: 07/09/19 Due: 07/09/20

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT04914117 Org: User:
Start: 11/29/21 End: 03/11/23 Due: 03/11/24

Evaluation of RC28-E Injection in Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT04782115 Org: User:
Start: 03/17/21 End: 07/31/23 Due: 07/31/24

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Phase: N/A Priority: Normal
NCT ID: NCT04400695 Org: User:
Start: 09/29/20 End: 12/30/24 Due: 12/30/25

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05943379 Org: User:
Start: 06/08/23 End: 12/01/26 Due: 12/01/27

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Phase: N/A Priority: Normal
NCT ID: NCT06456567 Org: User:
Start: 09/30/24 End: 05/31/27 Due: 05/31/28

A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06944496 Org: User:
Start: 05/15/25 End: 05/15/30 Due: 05/15/31

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase: N/A Priority: Normal
NCT ID: NCT06155383 Org: User:
Start: 11/27/23 End: 12/31/27 Due: 12/31/28

A Study of Telitacicept in Patients with Primary Immunoglobulin A（IgA） Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT05799287 Org: User:
Start: 04/28/23 End: 12/31/25 Due: 12/31/26